A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon.

IF 5.3 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Molecular Therapy Oncolytics Pub Date : 2023-09-21 DOI:10.1016/j.omto.2023.08.010

Jia Yi, Peizhe Lin, Qingbo Li, Ao Zhang, Xianbin Kong

{"title":"A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon.","authors":"Jia Yi, Peizhe Lin, Qingbo Li, Ao Zhang, Xianbin Kong","doi":"10.1016/j.omto.2023.08.010","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer (CRC) has the third highest incidence and the second highest mortality in the world, which seriously affects human health, while current treatments methods for CRC, including systemic therapy, preoperative radiotherapy, and surgical local excision, still have poor survival rates for patients with metastatic disease, making it critical to develop new strategies for treating CRC. In this article, we found that the gut microbiota can modulate the signaling pathways of cancer cells through direct contact with tumor cells, generate inflammatory responses and oxidative stress through interactions between the innate and adaptive immune systems, and produce diverse metabolic combinations to trigger specific immune responses and promote the initiation of systemic type I interferon (IFN-I) and anti-viral immunity. In addition, oncolytic virus-mediated immunotherapy for regulating oncolytic virus can directly lyse tumor cells, induce the immune activity of the body, interact with interferon, inhibit the anti-viral effect of IFN-I, and enhance the anti-tumor effect of IFN-II. Interferon plays an important role in the anti-tumor process. We put forward that exploring the effects of intestinal flora and oncolytic virus on interferon to treat CRC is a promising therapeutic option.</p>","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"30 ","pages":"254-274"},"PeriodicalIF":5.3000,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2d/12/main.PMC10493895.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy Oncolytics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omto.2023.08.010","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Colorectal cancer (CRC) has the third highest incidence and the second highest mortality in the world, which seriously affects human health, while current treatments methods for CRC, including systemic therapy, preoperative radiotherapy, and surgical local excision, still have poor survival rates for patients with metastatic disease, making it critical to develop new strategies for treating CRC. In this article, we found that the gut microbiota can modulate the signaling pathways of cancer cells through direct contact with tumor cells, generate inflammatory responses and oxidative stress through interactions between the innate and adaptive immune systems, and produce diverse metabolic combinations to trigger specific immune responses and promote the initiation of systemic type I interferon (IFN-I) and anti-viral immunity. In addition, oncolytic virus-mediated immunotherapy for regulating oncolytic virus can directly lyse tumor cells, induce the immune activity of the body, interact with interferon, inhibit the anti-viral effect of IFN-I, and enhance the anti-tumor effect of IFN-II. Interferon plays an important role in the anti-tumor process. We put forward that exploring the effects of intestinal flora and oncolytic virus on interferon to treat CRC is a promising therapeutic option.

Abstract Image

查看原文本刊更多论文

调节肠道菌群和溶瘤病毒对干扰素的影响是治疗结直肠癌的新策略。

结直肠癌(Colorectal cancer, CRC)是世界上发病率第三高、死亡率第二高的疾病，严重影响着人类的健康，而目前对结直肠癌的治疗方法，包括全身治疗、术前放疗、手术局部切除等，对于转移性结直肠癌患者的生存率仍然很低，因此开发新的结直肠癌治疗策略至关重要。在本文中，我们发现肠道微生物群可以通过与肿瘤细胞的直接接触来调节癌细胞的信号通路，通过先天免疫系统和适应性免疫系统的相互作用产生炎症反应和氧化应激，并产生多种代谢组合来触发特异性免疫反应，促进全身I型干扰素(IFN-I)和抗病毒免疫的启动。此外，溶瘤病毒介导的调节溶瘤病毒的免疫治疗可直接裂解肿瘤细胞，诱导机体免疫活性，与干扰素相互作用，抑制IFN-I的抗病毒作用，增强IFN-II的抗肿瘤作用。干扰素在抗肿瘤过程中起着重要作用。我们提出探讨肠道菌群和溶瘤病毒对干扰素治疗结直肠癌的影响是一种很有前景的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Therapy Oncolytics Medicine-Oncology

CiteScore

10.90

自引率

3.50%

发文量

152

审稿时长

6 weeks

期刊介绍： Molecular Therapy — Oncolytics is an international, online-only, open access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer.